Introduction

The endocannabinoid system has recently emerged as a target for the pharmacological treatment of obesity and cardiometabolic risk factors\(^1\). The cannabinoid receptor subtype 1 (CB1) was the first identified and cloned cannabinoid receptor. Further studies revealed that this receptor is a G-protein coupled receptor\(^2\). Among the antagonists of the CB1 receptor, rimonabant [N-piperido-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide; SR141716] is the first one to come into clinical use for treatment of multiple cardiovascular risk factors such as obesity, diabetes, hyperlipidemia and low high-density-lipoprotein (HDL) cholesterol\(^3\). The central nervous system is enriched with the CB1 receptors. Blockade of CB1 receptor in the central nervous system, especially the hypothalamus, results in decreased food intake\(^4\). Furthermore, CB1 receptors are also present in peripheral tissues and blockade of peripheral CB1 might also contribute to its metabolic effects. For instance, CB1 blockade in adipose tissue induces decreased abdominal fat, increased adiponectin and HDL, decreased triglycerides (TG), low-density lipoprotein (LDL), C-reactive protein (CRP), decreased insulin resistance and glycosylated hemoglobin\(^5\). Rimonabant also stimulates 2-deoxyglucose uptake in skeletal muscle cells\(^6\). It has been reported that there are also CB1 receptors in the cardiovascular system. Its role in the cardiovascular system and the effect of CB1 blockade are the focus of many recent researches. It has been shown that vascular and myocardial CB1 contribute to the modulation of blood pressure and heart

Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway

Nan-lan HUANG\(^3\), Jyh-ming JUANG\(^2\), Yi-ho WANG\(^3\), Chia-hsiang HSUEH\(^3\), Yao-jen LIANG\(^3\), Jiunn-lee LIN\(^2\), Chia-ti TSAI\(^1\), *

Ling- ping LAI\(^1, 2\), *

1Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan, China; 2Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, China; 3Department and Institute of Life Science, Fu-Jen Catholic University, Taipei, Taiwan, China

Aim: To investigate whether rimonabant, a cannabinoid receptor antagonist, had inhibitory effects on inflammatory reactions in human umbilical vein endothelial cells (HUVEC).

Methods: TNF-α-induced IL-6 production was measured by ELISA and effects on related signaling pathways were investigated by immunoblot analysis. Cellular cAMP level was measured using kinase-coupled luciferase reaction.

Results: Rimonabant at 1 and 10 μmol/L significantly inhibited TNF-α-induced IL-6 production when added 15, 30 and 60 minutes before TNF-α treatment. Rimonabant also inhibited TNF-α-induced phosphorylation of IkB kinase (IKK) α/β and IkB-α degradation. ACEA, a cannabinoid receptor subtype 1 (CB1) agonist, added before rimonabant abolished the former effects of rimonabant. H-89, an inhibitor of cAMP-dependent protein kinase (PKA), abolished the inhibitory effects of rimonabant on TNF-α induced IL-6 production. Rimonabant also increased the phosphorylation of PKA regulatory subunit II (PKA-RII), implying the essential role of PKA activation in the inhibitory effects of rimonabant. Treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin did not abolish the inhibitory effects of rimonabant on TNF-α induced IL-6 production.

Conclusion: Rimonabant had anti-inflammatory effects on endothelial cells and inhibited TNF-α-induced IKKα/β phosphorylation, IkB-α degradation and IL-6 production in HUVEC. This effect was related to CB1 antagonism and PKA activation.

Keywords: rimonabant; CB1 receptor; cAMP-dependent protein kinase; endothelial cells; inflammation
Atherosclerosis is an important disease world-wide and it is the primary cause of many cardiovascular diseases including coronary artery disease, stroke, peripheral arterial occlusive disease and so on. There is growing evidence showing that atherosclerosis is an inflammatory disease. Increased expression of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in arterial wall does not only reflect an inflammation status but also participates in the pathogenesis of atherosclerosis. For instance, it has been shown that IL-6 enhanced fatty lesion development in mice. Several drugs useful in treatment of cardiovascular diseases, such as HMG-CoA reductase inhibitors and metformin, have been proved to possess anti-inflammatory effects.

In the present study, we investigate the possible anti-inflammatory effect of rimonabant in endothelial cells with a hope that this could be a potential novel treatment strategy for atherosclerosis. We used human umbilical vein endothelial cells (HUVEC) to investigate whether rimonabant suppressed the inflammatory responses in vascular endothelial cells. TNF-α was used to induce an inflammatory reaction in HUVEC. The effects of rimonabant and the potential roles of the CB1 receptor signal pathways were also studied.

Materials and methods

Materials
Goat anti-rabbit IgG and anti-mouse IgG antibodies, β-actin, α-tubulin, IκB-α monoclonal antibodies and IKKα/β polyclonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit phospho-PKA-RII (Ser180)/IKKβ (Ser180) monoclonal antibody was purchased from Millipore Corporation and rabbit CB1 receptor polyclonal antibody from CHEMICON® International, Inc (Upstate, Temecula, CA, USA). Phospho-IKKα(Ser180)/IKKβ(Ser180) polyclonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell isolation and culture experiments
HUVEC were obtained from umbilical cords, digested with 0.05% of type II collagenase (Sigma Chemical Co, St Louis, MO, USA), and eluted with Medium199. Isolated HUVEC were cultivated in 20% fetal bovine serum (FBS; Biological Industries, Kibbutz Be’er Haemek, Israel) in M199 with endothelial cell growth supplement (ECGS, Upstate, Lake Placid, NY, USA) until confluent.

Passage 3–5 of HUVEC was incubated with 2% FBS in M199 for another 12–16 h and treated with rimonabant (Sanofi-Aventis, Montpellier, France) was added for 16–24 h before the experiments with 20% FBS in M199. After 12–16 h of transfection, the cells were incubated with 2% FBS in M199 for another 12–16 h and treated with rimonabant and TNF-α as indicated.

Transfection of small interfering RNA into HUVEC
Transfection of siRNA against cannabinoid receptor type 1 (CB1 siRNA, sense: 5'-UUCGUACUGAAUGUCAUUUGAGCCC-3', anti-sense: 5'-GGGCUCAAAUGACAUCAUCAUGACGAA-3'; Invitrogen™) into HUVEC was accomplished using Turbofect™ in vitro transfection reagent (Fermentas). After 12–16 h of transfection, the cells were incubated with 2% FBS in M199 for another 12–16 h and treated with rimonabant and TNF-α as indicated.

Statistical analysis
Parametric data were normalized to the level of TNF-α alone, presented as mean±SEM and analyzed by t-test using Sigma-Plot 9.0. A P<0.05 was considered statistically significant.
Results

Rimonabant (SR141716) inhibits TNF-α-induced IL-6 upregulation, IKKα/β phosphorylation and IκB-α degradation in endothelial cells

To examine the effect of rimonabant on TNF-α-induced IL-6 upregulation in HUVEC, we first performed concentration and time course experiments with rimonabant at 0.1, 1, or 10 μmol/L, added 15, 30 minutes or 1 hour prior to incubation with TNF-α (10 ng/mL). Rimonabant significantly inhibited TNF-α-induced upregulation of IL-6 at 1 μmol/L and 10 μmol/L in all three time course experiments (Figure 1).

Because NF-κB pathway activation participates in TNF-α-induced IL-6 production in endothelial cells, we investigated the effect of rimonabant on TNF-α-induced NF-κB pathway activation. Treatment with TNF-α (10 ng/mL) for 15 min resulted in a significant increase of phosphorylation of IKKα/β (Figure 2A) and degradation of IκB-α (Figure 2B). Both the increment of IKKα/β phosphorylation and the degradation of IκB-α induced by TNF-α were significantly reversed by 1 and 10 μmol/L of rimonabant. Treatment with rimonabant alone did not influence cellular level of IκB-α and IKK phosphorylation (Figure 2C).

The endothelial CB1 receptor is involved in the anti-inflammatory effects of rimonabant

Because rimonabant significantly reduced TNF-α induced changes, we examined whether the receptor of rimonabant was present in HUVEC. Immunoblotting of total cellular lysates from HUVEC and the neuroblastoma SH-SY5Y cells (serving as positive control) both demonstrated the existence of CB1 receptor (Figure 3A).

Since rimonabant is a competitive antagonist of human CB1 receptor, we tested whether the effects of rimonabant were blocked by ACEA, a CB1 agonist. ACEA (10 μmol/L) was added either before or after treatment with rimonabant (10 μmol/L), which was followed by treatment with TNF-α. We demonstrated that ACEA blocked the inhibitory effects of rimonabant on TNF-α-induced IL-6 secretion (Figure 3B) only when it was added before rimonabant treatment. Pre-treatment with ACEA also reversed the inhibitory effects of rimonabant on IKKα/β phosphorylation (Figure 3C). These results suggested the involvement of CB1-binding in the effects of rimonabant. Treatment with ACEA alone did not significantly influence the secretion of IL-6 (Figure 3B).

Figure 1. Rimonabant inhibited TNF-α-induced IL-6 secretion in a concentration-dependent manner. HUVEC was incubated with vehicle (DMSO) or rimonabant (0.1–10 μmol/L; Rimo) for 15 min (A), 30 min (B), or 1 h (C) before 24-h incubation with TNF-α. ELISA data were normalized to the levels of TNF-α at 10 ng/mL and expressed as mean±SEM (n=6–9). bP<0.05, cP<0.01 vs TNF-α alone.

Figure 2. Effects of rimonabant on TNF-α-induced NF-κB signal pathway. HUVEC was incubated with vehicle (DMSO) or rimonabant (1–10 μmol/L) for 30 min before incubation with TNF-α for 15 min. Cellular proteins were subjected to immunoblot analysis for measurement of phospho-IKKα/β (A) and IκB-α (B). Data were normalized to the level of TNF-α alone and presented as mean±SEM (n=3–4). bP<0.05, cP<0.01 vs TNF-α alone. (C) Immunoblot of phospho-IKKα/β (normalized to IKKα/β, n=5) and IκB-α (normalized to α-tubulin, n=4) after treatment with either vehicle (DMSO) or rimonabant (1–10 μmol/L). There is no significant difference between vehicle and rimonabant group.
The roles of protein kinases downstream of the CB1 receptor

It has been reported that PKA is the downstream candidate of the CB1 receptor signal pathway\(^{[11]}\). Activation of CB1 receptor decreases the activity of PKA by the CB1-coupled G protein. Therefore, theoretically, inhibition of CB1 receptor by rimonabant should increase cellular cAMP and the activity of PKA.

To investigate the role of PKA in the inhibitory effects of rimonabant, H-89 (0.1–1 μmol/L) was applied to inhibit the PKA pathway. H-89 (0.3 and 1 μmol/L) abolished the inhibitory effects of rimonabant on the TNF-α-induced secretion of IL-6 (Figure 4A), indicating the participation of PKA activation. Immunoblot analysis demonstrated that phosphorylation of PKA-RII subunit was increased by rimonabant in a concentration-dependent manner (Figure 5A). The increase in phospho-PKA-RII by rimonabant was prevented by pre-treatment with ACEA. Cellular cAMP level significantly increased after treatment with 1 and 10 μmol/L of rimonabant (Figure 5B).

On the other hand, rimonabant was reported to enhance phosphatidylinositol 3-kinase (PI3K)/Akt activity in L6 cells. Whether rimonabant also influence PI3K/Akt pathway in endothelial cells was examined using the PI3K inhibitor wortmannin. Application of wortmannin (100 nmol/L), however, did not alter the inhibitory effects of rimonabant (Figure 4B).
CB1 silencing abolished the inhibitory effects of rimonabant on TNF-α-induced IL-6 secretion.

To figure out the role of CB1 receptor in the effects of rimonabant on endothelial cells, transfection of siRNA into HUVEC was conducted. Immunoblot demonstrated the silencing of CB1 receptor in HUVEC (Figure 6A). In contrast to the concentration-dependent inhibition of TNF-α-induced IL-6 by rimonabant in control cells, rimonabant did not inhibit the induced IL-6 secretion by HUVEC with decreased CB1 expression (Figure 6B). Accordingly, endothelial CB1 receptor was necessary to the effects of rimonabant.

Discussion

In recent trials, CB1 receptor blockade with rimonabant has been reported to improve multiple cardiometabolic risk factors in overweight individuals with comorbidities[1] and in abdominally obese patients with atherogenic dyslipidemia[12]. Whether rimonabant also inhibits vascular inflammation through CB1 receptor blockade is not full understood yet. It has been reported that rimonabant reduced plasma levels of the pro-inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1) and interleukin-12 (IL-12) in LDLR-/- mice fed a Western-type diet[13]. Positive modulation of circulating neutrophil and monocyte numbers, reduced platelet activation and lower levels of MCP-1 and regulated upon activation, normal T cell expressed and secreted (RANTES) by rimonabant in type 2 diabetic Zucker rats have also been reported[14]. We demonstrated that TNF-α-induced IL-6 production, IKKa/β phosphorylation and IκB-α degradation were significantly attenuated by rimonabant in HUVEC.

To investigate whether the effects of rimonabant were mediated through CB1 receptor, we first examined whether CB1 receptor was expressed in HUVEC. We chose the neuroblastoma SH-SY5Y cell line as a positive control in our experiments because the presence of CB1 receptor has been demonstrated by immunostaining and immunoblot analysis[15]. Protein lysate from SH-SY5Y and HUVEC were subjected to immunoblotting in juxtaposition. Blotting of protein from HUVEC revealed bands at the same molecular weight as that from SH-SY5Y cells, indicating the existence of CB1 receptor on HUVEC. Our results were in agreement with previous studies demonstrating the presence of CB1 receptor mRNA in endothelial cell culture[16] and CB1 protein on endothelial cells in isolated rat hearts[17]. Vascular endothelial cells in tissue samples collected from neurosurgery of patients were also positive for CB1 receptor by immunohistochemical examination[18].

Recherche et al elucidated rimonabant as an antagonist ligand, with nanomolar affinity for CB1 but micromolar affinity for CB2 in ligand binding assay[2, 19]. The dissociation constant of rimonabant for CB2 receptor was reported to be 13.2 μmol/L[11], a value that is higher than the effective concentration in the present study (1 μmol/L). Therefore, we assumed that the effects of rimonabant were likely mediated through CB1 receptor and ACEA was selected to examine whether CB1 receptor was involved in the effects of rimonabant. ACEA at 10 μmol/L was used in the experiments to selectively bind to CB1. This concentration was not high enough to block CB2
because inhibition of forskolin-stimulated cAMP production by ACEA in CHO cells stably transfected with CB2 receptor required a concentration higher than 10 μmol/L.[20] We found that ACEA reversed the stimulated IL-6 secretion and phosphorylation of IKKa/β when it was added prior to rimonabant, while the inverse did not.

Since the expression of CB1 receptor in HUVEC was shown, and the effects of CB1 agonist rimonabant was reversed by CB1 agonist ACEA, we transfected HUVEC with CB1 siRNA to confirm whether expression of CB1 receptor is essential in the effects of rimonabant. Silencing of CB1 receptor abolished the inhibitory effects of rimonabant on TNF-α-induced IL-6 production. Taken together, the effects of rimonabant on HUVEC may be attributed to blockade of basal level of Gβγ-coupled CB1 receptor activity. Based on this assumption we would expect to see similar change to rimonabant treatment when CB1 receptor is silenced. However, cellular signal transduction is complex and there may be some limitation in experiments. Since reduction in CB1 receptor do not change TNF-α induced effects, all we can figure out is that rimonabant inhibits these effects through CB1-binding action.

CB1 receptor is coupled to Gα and inhibits adenylate cyclase activity, reduces the production of cAMP and thereby attenuates the activity of PKA.[23] Rimonabant, as a CB1 agonist, may relieve the negative regulation of cAMP level and consequently enhance the PKA activity. Incubation with H-89 (0.1–1 μmol/L) was conducted to test whether PKA played a role in the anti-inflammatory effects of rimonabant. As demonstrated by IL-6 production, H-89 at 0.3 and 1 μmol/L abolished the effect of rimonabant. These concentrations were similar to the IC50 of H-89 for PKA (0.135 μmol/L).[21] It was reported that adiponectin inhibits TNF-α-induced endothelial hyperpermeability[24] and endothelial IL-8 synthesis[25]. These inhibitory effects of adiponectin are abrogated by PKA inhibitors, consistent with the present study using TNF-α and rimonabant. Therefore, rimonabant and adiponectin may share similar signaling in terms of anti-inflammatory effect in endothelial cells.

We further performed immunoblot studies on type II regulatory subunit of PKA (PKA-RII) in HUVEC. Phosphorylation of PKA-RII subunit was suggested to regulate PKA-dependent substrate phosphorylation[26]. Phospho-PKA-RII was increased by rimonabant. Pre-treatment with the CB1 agonist ACEA reversed the rimonabant-induced increase in phospho-PKA-RII, implicating the involvement of phosphorylation activity of endothelial type II PKA in the effects of the CB1 antagonist rimonabant. To the best of our knowledge, the present study is the first to illustrate the expression of PKA-RII and alteration in phospho-PKA-RII by CB1 signal pathway in vascular endothelial cells. Measurement of cellular cAMP also demonstrated increased level after rimonabant treatment, indicating that there may be basal or constitutive CB1 receptor activity to suppress cellular cAMP generation.

Akt activation by CB1 receptor antagonist rimonabant has been reported in L6 skeletal muscle cells and in mouse primary myocytes[24]. In these cells, rimonabant increased 2-deoxyglucose uptake, which was blunted by co-incubation with the PI3K inhibitor LY294002. In our experiments, we found that treatment with the PI3K inhibitor wortmannin had no effects on the inhibition of IL-6 induction by rimonabant, suggesting that PI3K/Akt pathway was not involved in the effects of rimonabant on HUVEC. The discrepancy might be related to different cell types.

In summary, we demonstrated the inhibitory effects of rimonabant on TNF-α-induced NF-κB pathway activation and IL-6 production. These effects of rimonabant might be attributed to blockade of CB1 receptor and the subsequent activation of cAMP/PKA pathway. These effects might serve as a new therapeutic strategy for atherosclerosis.

Acknowledgements
This study was supported in part by a grant from the National Taiwan University Hospital NTUH(97S805).

Author contribution
Nan-lan HUANG and Chia-ti TSAI designed the research; Nan-lan HUANG and Yi-ho WANG performed the experiments; Jyh-ming JUANG, Jiunn-lee LIN, Yao-jen LIANG, and Chia-hsiang HSUEH contributed to reagents or analytic tools; Nan-lan HUANG analyzed the data and wrote the article; Chia-ti TSAI and Ling-ping LAI revised the article.

References
1. Aronne LJ, Isoldi KK. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: Efficacy. Am J Cardiol 2007; 100: S18–S26.
2. Howlett AC. Pharmacology of Cannabinoid Receptors. Annu Rev Pharmacol 1995; 35: 607–34.
3. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919–26.
4. Esposito I, Proto MC, Gazzerno P, Laeza C, Miele C, Alberobello AT, et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008; 74: 1678–86.
5. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008; 153: 290–98.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95.
7. Tegdé A, Mallat Z. Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways. Physiol Rev 2006; 86: 515–81.
8. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28: 664–72.
9. Moya NL, Chiang SH, Hsueh CH, Lin YJ, Chen YJ, Lai LP. Metformin inhibits TNF-α-induced iκB kinase phosphorylation, iκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009; 134: 169–75.
10. Liang YJ, Shyu KG, Wang BW, Lai LP. C-reactive protein activates the nuclear factor-κB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 2006; 40: 412–20.
11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of...
Cannabinoid Receptors. Pharmacol Rev 2002; 54: 161–202.

12 Després JP, Ross R, Boka G, Alméras N, Lemieux I. ADAGIO-Lipids Investigators. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416–23.

13 Dol-Gleizes F, Paumelle R, Visentin V, Marés A-M, Desitter P, Hennuyer N, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29: 12–18.

14 Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008; 154: 1047–54.

15 Marini P, Moriello AS, Cristino L, Palmery M, Di Marzo V. Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SYSY cells: Interactions with muscarinic and [delta]-opioid receptors. Biochim Biophys Acta 2009; 1793: 1289–303.

16 Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998; 243: 838–43.

17 Lepine P, Lagneux C, Sirois MG, Lamontagne D. Endothelial CB1 receptors limit infarct size through NO formation in rat isolated hearts. Life Sci 2007; 81: 1373–80.

18 Schley M, Ständer J, Kerner D, Vajkoczy P, Schüpfner G, Dusch M, et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 2009; 79: 333–37.

19 Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240.

20 Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999; 289: 1427–33.

21 Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006; 24: 261–74.

22 Xu SQ, Mahadev K, Wu X, Fuchsel L, Donnelly S, Scalia RG, et al. Adiponectin Protects Against Angiotensin II or Tumor Necrosis Factor α-Induced Endothelial Cell Monolayer Hyperpermeability: Role of cAMP/PKA Signaling. Arterioscler Thromb Vasc Biol 2008; 28: 899–905.

23 Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, Kihara S, et al. Adiponectin Inhibits Endothelial Synthesis of Interleukin-8. Circ Res 2005; 97: 1245–52.

24 Manni S, Mauban JH, Ward CW, Bond M. Phosphorylation of the PKA regulatory subunit modulates PKA-AKAP interaction, substrate phosphorylation and calcium signaling in cardiac cells. J Biol Chem 2008; 283: 24145–54.